Onpattro® (patisirna) is the first siRNA drug, approved by the FDA in 2018, for the treatment of hereditary amyloidogenic transthyretin (ATTRv) amyloidosis, which is caused by mutation of the transthyretin (TTR) gene and misfolded aggregates of TTR protein in liver [72,73]. This evidence concerns the gene TTR and prealbumin measurement.